Jeffrey J. Kooijman

Oss, NB, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Combined cellular and biochemical profiling of Bruton's tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers.

Combined cellular and biochemical profiling of Bruton's tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers.

Journal: Frontiers in oncology

Published: July 16, 2025

Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines.

Selective CK1α degraders exert antiproliferative activity against a broad range of human cancer cell lines.

Journal: Nature communications

Published: May 01, 2023

Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor.

Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor.

Journal: Cancer chemotherapy and pharmacology

Published: February 10, 2023

Multi-omics analyses of MEN1 missense mutations identify disruption of menin-MLL and menin-JunD interactions as critical requirements for molecular pathogenicity.

Multi-omics analyses of MEN1 missense mutations identify disruption of menin-MLL and menin-JunD interactions as critical requirements for molecular pathogenicity.

Journal: Epigenetics & chromatin

Published: June 27, 2022

Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020.

Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020.

Journal: Frontiers in oncology

Published: May 25, 2022

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.

Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.

Journal: British journal of cancer

Published: August 07, 2020

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017.

Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017.

Journal: Molecular cancer therapeutics

Published: August 03, 2018

Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors.

Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors.

Journal: Molecular cancer therapeutics

Published: June 22, 2016

Showing 1-8 of 8

Last Updated: 09/26/2026